Late yesterday Johnson & Johnson submitted a request for an emergency use authorization (EUA) for its COVID-19 candidate.
If the EUA is granted by the Food and Drug Administration (FDA), the vaccine will become the third COVID-19 vaccine approved for use in the United States, and the first that requires only one dose.Last week Johnson & Johnson released results from a phase 3 trial of the drug that showed an overall efficacy rate of 66%.
The vaccine, however, was more than 85% effective in preventing severe illness from COVID-19 infections and 100% effective in preventing hospitalizations and deaths. "Upon authorization of our investigational COVID-19 vaccine for emergency use, we are ready to begin shipping," said Paul Stoffels, MD, the